Monimus Capital Management LP Takes Position in Spero Therapeutics, Inc. (NASDAQ:SPRO)

Monimus Capital Management LP purchased a new stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 310,908 shares of the company’s stock, valued at approximately $320,000.

Insiders Place Their Bets

In other Spero Therapeutics news, Director Ankit Mahadevia sold 69,219 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $53,990.82. Following the sale, the director now directly owns 689,866 shares in the company, valued at $538,095.48. This represents a 9.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Sath Shukla sold 155,333 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total transaction of $121,159.74. Following the sale, the chief executive officer now owns 1,736,883 shares in the company, valued at approximately $1,354,768.74. This trade represents a 8.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 245,241 shares of company stock worth $191,288 in the last ninety days. 4.52% of the stock is owned by corporate insiders.

Spero Therapeutics Stock Up 0.5 %

Spero Therapeutics stock opened at $0.78 on Friday. The firm has a market cap of $42.65 million, a PE ratio of 11.18 and a beta of 0.68. Spero Therapeutics, Inc. has a 52-week low of $0.73 and a 52-week high of $1.84. The company’s 50 day moving average is $0.85 and its two-hundred day moving average is $1.10.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SPRO. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. Evercore ISI lowered shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective on the stock. in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Spero Therapeutics in a report on Thursday, January 30th. Finally, TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.